Process Controls in Microbiology: Internal Amplification Controls and Their Role

Process controls, specifically internal amplification controls (IACs), are defined as non-target nucleic acid sequences co-amplified in the same reaction tube as the target analyte to monitor for PCR inhibition, reagent failure, and thermal cycler malfunction in microbiology assays. An IAC is useful whenever a negative result must be interpreted with confidence—particularly in diagnostic, environmental, or food microbiology PCR workflows where sample matrices may contain inhibitors. Unlike external positive controls run in separate tubes, an IAC is added directly to each sample reaction, providing a per-reaction quality check that distinguishes true negatives from false negatives caused by inhibition or technical failure.

At a Glance

Scientific Principle of Internal Amplification Controls

The fundamental principle underlying IACs is that a known, non-target nucleic acid sequence is co-amplified alongside the target of interest within the same reaction vessel. If the IAC amplifies successfully (producing a detectable signal), the reaction components and thermal cycling conditions were functional for that sample. If the IAC fails to amplify, the result for the target is considered invalid, regardless of whether target signal is present or absent. This per-reaction quality check is essential because inhibitors such as heme, humic acids, polysaccharides, urea, or residual extraction chemicals can vary unpredictably between individual samples, even when processed in the same batch [1].

Two major IAC formats exist. In a competitive IAC, the control sequence uses the same primer binding sites as the target but contains a different internal sequence, allowing differentiation by probe or size. This design forces the IAC and target to compete for the same primers, making the IAC sensitive to any condition that affects target amplification. In a non-competitive IAC, the control sequence uses a separate primer pair and probe, often targeting a synthetic or exogenous sequence not found in the sample. This format does not compete with the target but requires independent optimization to ensure the IAC reaction does not deplete polymerase or nucleotides needed for target amplification.

The choice between competitive and non-competitive IAC depends on the assay's stringency requirements and the expected inhibitor load. Competitive IACs provide a more direct measure of target amplification efficiency but require careful titration to avoid outcompeting low-abundance targets. Non-competitive IACs are simpler to design and optimize but may not detect all types of inhibition that affect the target reaction specifically.

Materials and Instrumentation Choices

IAC Template Construction

The IAC template is typically a synthetic DNA oligonucleotide, a linearized plasmid, or an in vitro transcribed RNA (for RT-PCR applications). Synthetic oligonucleotides are the simplest option for DNA targets, but they lack the secondary structure of longer amplicons and may not accurately reflect amplification efficiency. Linearized plasmids offer better stability and can be quantified precisely by spectrophotometry or digital PCR. For RNA targets, in vitro transcribed RNA IACs must be treated with DNase to remove template DNA and stored in aliquots at -80°C to prevent degradation.

Detection Platforms

The choice of detection platform influences IAC design. For real-time PCR (qPCR), the IAC requires a distinct fluorophore (e.g., VIC, HEX, or Cy5) that does not overlap with the target fluorophore (typically FAM). Multiplexing capability varies by instrument; older four-channel instruments may limit the number of targets that can be monitored simultaneously. For conventional PCR with endpoint detection, the IAC must produce an amplicon of distinctly different size from the target, resolvable by gel electrophoresis.

Reagent Systems

Commercial master mixes vary in their tolerance to inhibitors and their ability to support multiplex reactions. Some master mixes are formulated with additives (e.g., bovine serum albumin, betaine, or T4 gene 32 protein) that reduce inhibition, which may affect IAC performance. When selecting a master mix, verify that the manufacturer provides data on multiplex compatibility and inhibitor tolerance. The same master mix should be used for assay validation and routine testing, as switching formulations can alter IAC amplification efficiency [3].

Sample Preparation Methods

The extraction method directly impacts the inhibitor profile of the final eluate. Column-based purification removes many inhibitors but may co-elute ethanol or chaotropic salts if wash steps are incomplete. Bead-based methods can be more effective for difficult samples (e.g., stool, soil) but may introduce bead-derived inhibitors. Magnetic bead extraction systems often include internal process controls that monitor extraction efficiency separately from amplification. Laboratories should validate that their chosen extraction method, when combined with their IAC, reliably detects inhibition in representative sample matrices.

Controls Framework

A complete controls framework for PCR-based microbiology assays includes multiple layers beyond the IAC. The IAC serves as the per-reaction process control, but it must be interpreted alongside other controls to make valid conclusions.

No-Template Control (NTC)

The NTC contains all reaction components except template DNA. It detects reagent contamination with target or IAC sequences. If the NTC shows amplification of the IAC (which is expected if IAC is added to all reactions), the IAC signal must be distinguished from target signal. Some protocols add IAC only to sample reactions and not to NTCs, but this creates a gap in contamination monitoring. A better practice is to include IAC in NTCs and set a threshold for acceptable IAC signal in the absence of template.

Positive Extraction Control

A known positive sample (or a surrogate matrix spiked with target) processed through the entire workflow from extraction to amplification. This control verifies that the extraction method recovers nucleic acid and that the amplification system detects the target. The IAC in this control should amplify normally, confirming that the extraction did not introduce inhibitors.

Negative Extraction Control

A sample-free matrix (e.g., nuclease-free water or sterile buffer) processed through extraction and amplification. This control detects contamination introduced during extraction. The IAC should amplify in this control, confirming that the extraction reagents themselves are not inhibitory.

Inhibition Control

Some protocols include a separate reaction where a known amount of target (or IAC) is spiked into a replicate of the sample after extraction. If the spiked sample shows delayed amplification compared to the unspiked control, inhibition is present. This approach is more sensitive than IAC alone but doubles the number of reactions per sample.

IAC Titration

The IAC must be titrated to a concentration that amplifies reliably in clean samples but can be outcompeted or inhibited in problematic samples. A typical starting point is 10–100 copies per reaction for plasmid-based IACs. The IAC Ct value in uninhibited samples should be 3–5 cycles higher than the target's limit of detection, ensuring that the IAC does not mask weak target signals. For competitive IACs, the IAC concentration must be low enough that high-target samples do not completely suppress IAC amplification.

Conceptual Workflow

Step 1: IAC Design and Synthesis

Design the IAC sequence based on the assay format. For competitive IAC, modify the internal sequence between primer binding sites to create a distinct amplicon. For non-competitive IAC, select a sequence with no homology to the target or common sample organisms. Order the IAC as a synthetic gBlock or plasmid from a commercial supplier. Resuspend in TE buffer (pH 8.0) and quantify by UV spectrophotometry or fluorometry.

Step 2: IAC Validation

Test the IAC alone in a dilution series (10^5 to 1 copy per reaction) to establish amplification efficiency and limit of detection. Then test the IAC in combination with the target assay at various ratios to identify the optimal IAC concentration. Document the IAC Ct range for uninhibited samples. Validate that the IAC does not cross-react with the target probe or primers using BLAST analysis and empirical testing.

Step 3: Incorporation into Extraction

Add the IAC to the lysis buffer or extraction column at a consistent step in the protocol. For RNA targets, add the IAC as RNA before reverse transcription. For DNA targets, add the IAC as DNA before extraction. The IAC must be added at a step where it will experience the same chemical and enzymatic conditions as the target, including any inhibitors present in the sample.

Step 4: Amplification and Detection

Program the thermal cycler with the appropriate multiplex detection channels. Set the IAC fluorophore to a channel distinct from the target. Include NTC, positive extraction control, and negative extraction control in each run. Define acceptance criteria: the IAC must amplify within a predetermined Ct range (e.g., 28–32 cycles) for the sample result to be valid. If the IAC Ct exceeds the upper limit or is absent, the sample result is reported as "invalid due to inhibition."

Step 5: Result Interpretation

Interpret results using a decision matrix:

Quality Checks

Run Acceptance Criteria

Before interpreting individual sample results, verify that the entire run meets quality standards. The NTC must show no target amplification and IAC amplification within the expected range. The positive extraction control must show target amplification within the validated range. The negative extraction control must show no target amplification and IAC amplification within range. If any of these controls fail, the entire run is invalid and must be repeated.

Inter-Run Reproducibility

Monitor IAC Ct values across runs using a control chart. Establish a mean and standard deviation from at least 20 runs. A shift of more than 2 standard deviations in the IAC Ct of the positive extraction control may indicate reagent degradation, thermal cycler drift, or changes in extraction efficiency. Investigate and document any trends before continuing with clinical or research samples.

Lot-to-Lot Validation

When changing lots of master mix, primers, probes, or extraction kits, re-validate the IAC performance. Test at least 10 samples with known inhibition status using the old and new lots. The IAC Ct values should not differ by more than 1.5 cycles between lots. Document the comparison and obtain supervisory approval before implementing the new lot.

Matrix-Specific Validation

Each sample type (e.g., urine, stool, respiratory swab, environmental water) has a unique inhibitor profile. Validate the IAC performance in each matrix type using at least 20 representative samples. For matrices known to be highly inhibitory (e.g., stool, soil, plant tissue), consider using a more robust IAC format or adding an inhibitor removal step. The validation should include samples with known target concentrations to confirm that the IAC does not reduce assay sensitivity [5].

Result Interpretation

Distinguishing True Negatives from False Negatives

The primary function of the IAC is to distinguish true negatives from false negatives caused by inhibition. A sample with no target signal but a normal IAC signal is a true negative. A sample with no target signal and no IAC signal is invalid and should be re-extracted and re-tested, ideally with a diluted sample or an alternative extraction method.

High Target Concentration Effects

In samples with very high target concentration, the IAC may be outcompeted for primers (competitive IAC) or polymerase (non-competitive IAC). This is acceptable and does not invalidate the result, as the target signal confirms the presence of the analyte. However, if the IAC is consistently absent in high-positive samples, consider reducing the IAC concentration or switching to a non-competitive format.

Weak Target Signals

When the target signal is near the limit of detection, the IAC should still amplify normally. If the IAC is delayed or absent in samples with weak target signals, inhibition may be reducing the effective target concentration below the detection threshold. In this case, the result should be reported as "indeterminate" and the sample re-tested with a dilution or cleanup step.

Multiplex Interference

In multiplex reactions, the IAC may interfere with target amplification or vice versa. Monitor for shifts in target Ct values when IAC is present versus absent. If the IAC causes a delay of more than 2 cycles in target amplification, reduce the IAC concentration or redesign the IAC to use a different primer set.

Troubleshooting

Limitations

Incomplete Inhibition Detection

The IAC cannot detect all types of inhibition. Some inhibitors affect the target and IAC differently, particularly if the IAC is shorter or has different GC content than the target. A sample may show normal IAC amplification but still have reduced target amplification due to sequence-specific inhibition. This limitation is inherent to all IAC formats and underscores the need for matrix-specific validation.

Competitive IAC Bias

Competitive IACs can underestimate inhibition in samples with low target concentration because the IAC and target compete for the same primers. If the target is absent, the IAC may amplify more efficiently than it would in the presence of target, masking mild inhibition. This bias can be minimized by using a non-competitive IAC or by validating the IAC at multiple target concentrations.

Cost and Complexity

Adding an IAC to every reaction increases reagent costs and complicates assay design, particularly for multiplex reactions with limited fluorophore channels. The IAC also requires additional validation steps during assay development. For low-throughput or research-only applications, external controls may be sufficient, but for diagnostic or regulatory testing, the IAC is essential.

False Confidence

A passing IAC does not guarantee that the target was successfully extracted or amplified. The IAC is added at a known concentration, whereas the target may be present at very low levels that are lost during extraction or inhibited by factors that do not affect the IAC. The IAC is a process control, not a recovery control. For quantitative assays, a separate recovery control (e.g., a spiked exogenous target) is needed to monitor extraction efficiency.

Documentation Requirements

Assay Validation Report

Document the IAC design, including sequence, length, GC content, and primer/probe binding sites. Record the IAC concentration used per reaction and the rationale for that concentration. Include data from IAC titration experiments, multiplex compatibility testing, and matrix-specific validation. The report should specify acceptance criteria for IAC Ct values in each sample type.

Standard Operating Procedure (SOP)

Write a detailed SOP that specifies:

• IAC preparation and storage conditions
• Step at which IAC is added to the workflow
• Thermal cycler program with IAC detection channel settings
• Acceptance criteria for IAC in NTC, positive controls, negative controls, and samples
• Procedure for handling invalid results (re-extraction, dilution, or alternative method)
• Frequency of IAC lot validation

Run Records

For each PCR run, record:

• Date, operator, and instrument ID
• IAC lot number and concentration
• Ct values for IAC in all controls and samples
• Any deviations from acceptance criteria and corrective actions taken
• Final result interpretation for each sample

Deviation and Corrective Action Log

Maintain a log of all IAC failures, including the date, sample type, observed Ct values, suspected cause, and corrective action. Review this log quarterly to identify trends that may indicate systemic issues with extraction reagents, master mix lots, or thermal cycler performance.

Biosafety Considerations

BSL-1 Scope

The IAC constructs described in this article are synthetic nucleic acids or plasmids derived from non-pathogenic organisms. Their handling falls within BSL-1 containment as defined by the CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL) [6]. Standard microbiological practices apply: wear lab coats and gloves, work on disinfected surfaces, and decontaminate waste before disposal.

Recombinant DNA Considerations

If the IAC is constructed using recombinant DNA techniques (e.g., cloning into a plasmid vector), the work must be reviewed by the institutional biosafety committee (IBC) in accordance with the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules [7]. Most IAC plasmids are exempt from full review because they contain no sequences that encode toxins or virulence factors, but institutional policy may require registration.

Waste Disposal

IAC-containing reaction tubes and extraction waste should be treated as potentially contaminated with sample nucleic acids. Decontaminate by autoclaving or by soaking in 10% bleach (0.5% sodium hypochlorite) for at least 30 minutes before disposal. Do not pour IAC solutions down the drain without decontamination.

Training

Personnel handling IACs should receive training in aseptic technique, pipetting accuracy, and PCR contamination prevention. Training should include the proper use of dedicated PCR workstations, filter tips, and separate areas for pre- and post-amplification work. Document training in the laboratory's training records.

Frequently Asked Questions

Q1: Can I use the same IAC for different target assays? Yes, a non-competitive IAC with its own primer pair can be used across multiple target assays, provided the IAC primers do not cross-react with any target primers or sample nucleic acids. Validate the IAC with each new target assay to confirm no interference. A competitive IAC is specific to the target primer set and cannot be transferred between assays.

Q2: How do I choose between a competitive and non-competitive IAC? Choose a competitive IAC when you need the most sensitive indicator of target amplification efficiency, particularly for quantitative assays where inhibition could bias results. Choose a non-competitive IAC when you need simplicity, when the assay uses multiple target primer pairs, or when the target is present at very low levels and competition could suppress detection. Non-competitive IACs are easier to design and validate but may not detect all forms of inhibition.

Q3: What should I do if my IAC consistently fails in a specific sample type? First, confirm that the failure is due to inhibition and not to IAC degradation or pipetting error. Test the sample eluate spiked with IAC post-extraction. If the IAC still fails, the sample matrix contains inhibitors that are not removed by the current extraction method. Options include: diluting the sample 1:5 or 1:10, adding BSA or T4 gene 32 protein to the master mix, switching to a different extraction method (e.g., bead-beating or phenol-chloroform), or using a PCR master mix formulated for inhibitor-rich samples.

Q4: How often should I re-validate my IAC? Re-validate the IAC whenever you change any component of the workflow: master mix lot, primer/probe lot, extraction kit lot, thermal cycler, or sample type. Perform a full re-validation at least annually, even if no changes have been made, to detect gradual reagent degradation or instrument drift. Document all re-validations in the assay validation file.

References and Further Reading

1. Optimizing data-driven excellence: Canada's approach to using pathogen test datasets for quality control, pipeline development and training initiatives
2. Decoding the seminal microbial fingerprint and semen quality: insights from the first Greek pilot study
3. Evaluation and comparison of three qPCR commercial assays and three automated platforms for the detection of monkeypox virus DNA
4. Recolonization dynamics of the middle ear microbiota following MESNA-assisted dissection in pediatric cholesteatomatous chronic otitis media
5. Analytical validation of a highly accurate and reliable next-generation sequencing-based urine assay
6. Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th Edition
7. NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules
8. NCBI Bookshelf: Molecular Biology and Laboratory Methods

Related Articles

• How to Set Up Positive and Negative Controls in a Microbiology Experiment
• Biosafety Cabinet Types and Selection Guide for Microbiology Laboratories
• How to Perform a KOH Test for Gram Reaction: Principle and Protocol
• Contamination Control in the Microbiology Lab: Sources, Prevention, and Detection
• Quality Control in the Microbiology Laboratory: Key Practices for Reliable Results
• How to Store and Handle Agar Plates and Culture Media for Microbiology